Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find University Hospitals Doctors
Daniel Spratt, MD

Daniel Spratt, MD

Office Locations

UH Seidman Cancer Center (0 mi.)

11100 Euclid Ave
Lower Level Ste S600
Cleveland, OH 44106

UH Seidman Cancer Center (0 mi.)

11100 Euclid Ave
Cleveland, OH 44106

UH Seidman Cancer Center Humphrey (0 mi.)

11100 Euclid Ave
Cleveland, OH 44106

UH Seidman Minoff Health Center (7 mi.)

3909 Orange Pl
Ste 1100
Beachwood, OH 44122

UH Seidman Parma Medical Arts Building 3 (11 mi.)

6525 Powers Blvd
Medical Arts Cntr 3 Ste 100
Parma, OH 44129

UH Seidman Mentor Health Center (20 mi.)

9485 Mentor Ave
Ste 3
Mentor, OH 44060

UH Seidman Avon Health Center (22 mi.)

2075 Healthway Dr
1st Floor
Avon, OH 44011

UH Seidman Portage Medical Center (29 mi.)

6847 N Chestnut St
Medical Arts Ste 10
Ravenna, OH 44266

Biography: Daniel Spratt, MD


  • Biomarkers
  • Bladder Cancer
  • Clinical Trials
  • Genitourinary Oncology
  • Kidney Cancer
  • Prostate Cancer
  • Spine Metastases
  • Stereotactic Body Radiation Therapy (SBRT)
  • Urologic Oncology


  • Chair, Department of Radiation Oncology, UH Cleveland Medical Center
  • Professor, CWRU School of Medicine
  • Vincent K. Smith Chair in Radiation Oncology, UH Seidman Cancer Center

Certifications & Memberships

  • Radiation Oncology - American Board of Radiology


Residency | Radiation Oncology
Radiation Oncology - Memorial Sloan-Kettering Cancer Center (2011 - 2015)

Internship | Radiation Oncology
Radiation Oncology - Spartanburg Regional Healthcare System (2010 - 2011)

Medical Education
Vanderbilt University School Of Medicine (2006 - 2010)

Georgia State University (2006)


Dan Spratt, MD, is a board-certified, international expert in the management of prostate cancer. Dr. Spratt attended Vanderbilt University (Nashville, Tennessee) for his medical training and completed his Radiation Oncology residency at Memorial Sloan Kettering (New York, New York). He joined the University of Michigan in 2015, where he developed a large NIH-funded translational and clinical research group.

While at the University of Michigan, Dr. Spratt also served as the Associate Chair for Clinical Research, the co-Chair for Genitourinary Clinical Trials for the Rogel Cancer Center, and the founding co-Director of the Spine Oncology Program. In addition, Dr. Spratt held leadership roles in the NIH Prostate SPORE and the U10 LAPS grant for cooperative group trials. Dr. Spratt received a number of awards in recognition for his teaching, mentorship, research and service during his time at University of Michigan. Furthermore, he was promoted to a tenured full professor faster than any other faculty member at the university, obtaining tenure in just five years following the completion of his training at Memorial Sloan Kettering.

Dr. Spratt currently serves as chair of the Department of Radiation Oncology at University Hospitals Cleveland Medical Center, and he joined the faculty of Case Western Reserve University School of Medicine in 2021. He also holds the Vincent K. Smith Chair in Radiation Oncology. Dr. Spratt’s clinical expertise encompasses the management of genitourinary cancers (prostate, bladder, kidney, and testicular), metastasis-directed radiotherapy, and spine stereotactic body radiotherapy. Patients travel from all over the world to seek his expert care for these conditions.

Dr. Spratt’s research expertise centers on the development and validation of prognostic and predictive biomarkers used to personalize treatment of cancer patients while avoiding over- and under-treatment. He has published over 300 peer-reviewed manuscripts, including practice-changing work in the New England Journal of Medicine, JAMA, Lancet Oncology, JAMA Oncology and the Journal of Clinical Oncology. Dr. Spratt has received federal funding from the NIH, Department of Defense, and numerous foundations for his research. He is the principal or co-principal investigator on over 10 institutional, national or multi-national clinical trials.

Dr. Spratt serves as the Intact Prostate Cancer Lead for the NRG Oncology Genitourinary Subcommittee and is a member of the National Cancer Institute’s Genitourinary Steering Committee. Presently, he is also the Senior Editor for radiation oncology’s primary biomedical journal, the International Journal of Radiation Biology and Physics. In addition, he serves on study sections for the NIH, Department of Defense, Prostate Cancer Canada, Prostate Cancer United Kingdom, and multiple other national foundations, while also serving as a reviewer for over 25 journals. Dr. Spratt has mentored over 30 undergraduates, graduate students, medical students, residents, fellows and junior faculty. He regularly receives invitations from all over the world to give lectures on the management and personalization of prostate cancer.

Dr. Spratt’s primary professional goal is to create a world-class Department of Radiation Oncology that provides cutting edge personalized and compassionate care.


2014 – ASTRO’s 56th Annual Basic Science Abstract Award in the Biology
2016 – Association of Residents in Radiation Oncology (ARRO) Teacher of the Year Award
2017 – Annual Clinical Faculty Teacher of the Year Award
2018 – Dean’s Award for Clinical Research
2018 – ASTRO’s Steven Liebel Award
2019 – Graduate Medical Education’s Teacher/Mentor of the Year Award
2019 – Cancer Clinical Investigator Team Leadership Award (CCITLA) National Institutes of Health Award
2020 – Outstanding Clinical Research Award, Rogel Cancer Center

Featured Videos

Watch to find out more about this University Hospitals provider.

Related Blog Articles

Illustration of cancer cells

Radiation Therapy Offers Targeted Treatment, Fewer Side Effects

Many patients require fewer treatments, with greater precision to kill cancer cells while preserving healthy tissue.

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Daniel Spratt did not disclose any Outside Relationships with Industry.